NCT00974896View on ClinicalTrials.gov

QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

April 30, 2011

Conditions

Advanced MalignancyAdvanced Solid TumorsCancerSolid TumorsTumors

Interventions

DRUG

AMG 479

AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).